

Zynteglo[®] (betibeglogene autotemcel) Medication Precertification Request Page 1 of 2

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: <u>1-866-752-7021</u> (TTY:<u>711</u>) FAX: 1-888-267-3277

For Medicare Advantage Part B: Please Use Medicare Request Form

Please indicate: Sta											
			f last treatment			F aye					
Precertification Request				Phor	ne:	Fax:					
First Name:	JN					DOB:					
Address:			Last Name:	City:		State:	-				
Home Phone:		Work Phone:		Cell Phone:		Email:					
Patient Current Weight: B. INSURANCE INFORM		kgs Patien	t Height: Inches	or <u> </u>	Allergies:						
			Does patient have oth		□ Yes □ No						
Aetna Member ID #: Group #:			If yes, provide ID#:	-							
Insured:	-										
Insured: Insured: Medicare: Yes No If yes, provide ID #: Medicaid: Yes No If yes, provide ID #:											
C. PRESCRIBER INFORM											
First Name:			Last Name:		(Check On	(Check One): 🗌 M.D. 🗌 D.O. 🗌 N.P. 🗌 P.A.					
Address:			-	City:		State:	ZIP:				
Phone:	Fax:		St Lic #:	NPI #:	DEA #:		UPIN:				
Provider Email:	I		Office Contact Name:	I	· · ·	Phone:	-				
Specialty (Check one):] Hematologi	st 🗌 Other: _									
D. DISPENSING PROVID											
Place of Administration:				Dispensing Provider/Pharmacy: Patient Selected choice							
Self-administered Physician's Office			☐ Physician's Office		ian's Office	Retail Pharmacy					
Outpatient Infusion Center Phone:			Specialty Pharmacy Other								
Center Name:			Name:								
Home Infusion Center				Address:							
Agency Name:				Phone:Fax:							
Administration code(s) (CPT):					TIN: PIN:						
E. PRODUCT INFORMAT	ION										
Request is for: Zynteglo (autotemcel) Do)se:	F	requency:						
F. DIAGNOSIS INFORMA		-									
Primary ICD Code:				-		ICD Code:					
G. CLINICAL INFORMAT			=								
For Initiation of Therapy (c	linical docum	entation required	<u>d):</u>			-					
☐ Yes ☐ No Has the patient been diagnosed with transfusion-dependent beta-thalassemia?											
Yes No Has genetic testing been done to confirm the genotype?											
└────────────────────────────────────											
\downarrow Yes \Box No Does the patient require regular blood cell transitions? \Box Yes \Box No In the past two years, has the patient received at least 100 milliliter per kilogram of packed red blood cells (pRBCs) per year?											
\downarrow Yes \square No In the past two years, has the patient received at least 8 transfusions events of packed red blood cells (pRBCs) per year?											
Yes No Is the patient eligible for a hematopoietic stem cell transplant (HSCT) but is unable to find a matched related donor?											
Yes No Has the patient received a prior hematopoietic stem cell transplant (HSCT)?											
 ☐ Yes ☐ No Has the patient previously received the requested medication or any other gene therapy? ☐ Yes ☐ No Is the patient reasonably anticipated to provide at least the minimum number of cells required to initiate the manufacturing process? 											
☐ Yes ☐ No is the patient reasonably anticipated to provide at least the minimum number of cells required to initiate the manufacturing process?											
Please indicate which of the following conditions applies to the patient:											
Positive for the present	nce of human i	immunodeficiency	virus type 1 or 2 (HIV-1	and HIV-2), he	patitis B virus (HBV), o	r hepatitis C (HC	SV)				
Any prior or current malignancy											
 Advanced liver disease (e.g., bridging fibrosis, cirrhosis, active hepatitis) Severely elevated iron in the heart (i.e., patients with cardiac T2* less than 10 msec by MRI) 											
\square None of the above											



Zynteglo[®] (betibeglogene autotemcel) Medication Precertification Request Page 2 of 2

 Aetna Precertification Notification

 Phone:
 <u>1-866-752-7021</u> (TTY:<u>711</u>)

 FAX:
 <u>1-888-267-3277</u>

(All fields must be completed and legible for precertification review.)

For Medicare Advantage Part B: Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB						
G. CLINICAL INFORMATION (continued	d) – Required clinical information must be o	completed in its <u>entirety</u> for all prec	ertification req	uests.					
□ Yes □ No Will the administration of the requested drug be provided at an Aetna designated gene therapy treatment center? Please indicate the designated gene therapy treatment center:									
H. ACKNOWLEDGEMENT									
Request Completed By (Signature Req	uired):		Date:	1	/				
, , , , , , , , , , , , , , , , , , ,	t for authorization of coverage of a medica erially false information or conceals mater	•	, ,						

The plan may request additional information or clarification, if needed, to evaluate requests.

insurance act, which is a crime and subjects such person to criminal and civil penalties.